Stocks of the Hour: SILK & Incannex

Company News

by Lauren Evans

SILK (ASX:SLA) secures $20m support from institutional investors

Beauty treatments provider SILK (ASX: SLA) has successfully raised $20 million by issuing 4.7 million new shares. The institutional placement offered securities at $4.30 per share. The price represents a discount of 5.1 per cent to the firm’s last closing price. The proceeds from the placement will partially fund the acquisition of Beauty Services Holdings.

Incannex (ASX:IHL) teams up with Vectura in product registration process

Medical cannabis researcher Incannex (ASX:IHL) is set to enter into a collaboration with London-listed pharmaceutical company Vectura Group in a bid to acquire regulatory approval for the ASX-listed company’s brain injury treatment. Under the partnership, Vectura will develop the specific formulation for IHL-216A required for clinical trials. IHL-216A is Incannex’s s proprietary inhaled drug designed to reduce damage from secondary brain injuries.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.